Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 11, 2016 8:55 AM ET

Pharmaceuticals

Company Overview of Fresenius Kabi USA, LLC

Company Overview

Fresenius Kabi USA, LLC develops, manufactures, and delivers pharmaceuticals and medical devices for critically and chronically ill patients. The company specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. It offers pharmaceuticals used in the treatment of various therapeutic areas, such as anti-infective, anesthesia/analgesia, critical care, and oncology for hospitals, long-term care facilities, alternate care sites, and clinics in North America. The company also provides medical devices in the areas of transfusion technologies, infusion pumps, therapeutic apheresis, plasmapheresis system, and cell processing. It sells its products through...

3 Corporate Drive

Lake Zurich, IL 60047

United States

Founded in 1996

Phone:

847-550-2300

Key Executives for Fresenius Kabi USA, LLC

Chief Executive Officer and President
Chief Financial Officer and Executive Vice President
Chief Operating Officer and Executive Vice President
Age: 60
President of Pharmaceuticals of North America Region
Age: 56
President of Medical Devices - Region North America
Compensation as of Fiscal Year 2015.

Fresenius Kabi USA, LLC Key Developments

Fresenius Kabi USA Appoints Seema Kumbhat as Senior Vice President and Medical Director

Fresenius Kabi USA announced that Seema Kumbhat, M.D., has joined the company as senior vice president and medical director. Dr. Kumbhat reports to John Ducker, president and CEO of Fresenius Kabi USA, and is a new member of the company’s executive committee. Dr. Kumbhat and her team will be responsible for pre-and post-launch clinical and medical strategies; clinically focused training and education and scientific exchange with stakeholders in the medical community. Dr. Kumbhat has more than 20 years of experience in health care. Before joining Fresenius Kabi, she held similar roles of increasing responsibility at Hospira, where she was global medical director, biosimilars, in clinical development and medical affairs and medical director, device development.

BD and Fresenius Kabi Announce Supply and Distribution Agreement

BD (Becton, Dickinson and Company) announced that Fresenius Kabi USA has acquired the BD Rx business, which includes a pharmaceutical manufacturing plant in Wilson, N.C., and the BD Simplist line of seven drugs in ready-to-administer prefilled glass syringes. BD and Fresenius Kabi have signed a 10-year supply and distribution agreement under which Fresenius Kabi will supply BD with a portfolio of intravenous solutions. Both BD and Fresenius Kabi plan to offer a range of IV solutions in the U.S. beginning in 2016.

Fresenius Kabi USA Introduces Moxifloxacin Injection 400 mg per 250 mL in Freeflex Bags

Fresenius Kabi USA introduced the anti-infective Moxifloxacin Injection 400 mg per 250 mL in Freeflex bags. The anti-infective Moxifloxacin Injection 400 mg per 250 mL is now available in the U.S. from Fresenius Kabi. Moxifloxacin is the third premix product Fresenius Kabi has introduced in the United States since 2013 using the company’s proprietary Freeflex delivery system. Freeflex is a non-PVC and non-DEHP flexible bag for infusion solutions using patented port technology and clear labeling. Moxifloxacin injection is indicated for the treatment of adults (18 years of age or older) with infections caused by susceptible isolates of the designated microorganisms in the conditions listed. Acute Bacterial Sinusitis; Acute Bacterial Exacerbation of Chronic Bronchitis; Community Acquired Pneumonia; Uncomplicated Skin and Skin Structure Infections; Complicated Skin and Skin Structure Infections; and Complicated Intra-Abdominal Infections.

Similar Private Companies By Industry

Company Name Region
Immune Response BioPharma, Inc. United States
Seaside Therapeutics, LLC United States
Lilly USA, LLC United States
Pure Encapsulations, Inc. United States
Nemean Pharma Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 8, 2016
Becton, Dickinson and Company, BD Rx Business
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Fresenius Kabi USA, LLC, please visit www.fresenius-kabi.us. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.